Pac Premier
You are here:  Home  >  Biotech  >  Current Article

Judge blocks sale of competitor for Amgen’s Enbrel

By   /   Friday, August 9th, 2019  /   Comments Off on Judge blocks sale of competitor for Amgen’s Enbrel

    Print       Email
A judge handed Thousand Oaks-based biotech giant Amgen a major win Aug. 9 when it permanently blocked sales of a competitor for its blockbuster rheumatoid arthritis drug Enbrel. The ruling in New Jersey District Court holds in place an injunction against Sandoz, a German division of Swiss multinational Novartis, blocking sales of its Enbrel biosimilar…


    This article is only available to Business Times subscribers
  • Subscribers: LOG IN or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

Revenue up at MannKind, but losses mount

Read More →